Protocol Ledger

NCT06979453 · Phase III · RECRUITING

A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis

Interventional Phase III clinical trial protocol NCT06979453 sponsored by Bristol Myers Squibb in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-12-03 Enrollment: 366 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06979453
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)366 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06979453
Protocol FieldVerified Registry Value
NCT IdentifierNCT06979453
Consolidated Lead SponsorBristol Myers Squibb
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment366 participants (ESTIMATED)
Registered Start Date2025-12-03
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06979453
Hospital Research SiteLocationSite Profile
Center for Dermatology Clinical Research, Inc.Fremont, CAOpen Hospital Dossier ->
Dermatology Research AssociatesLos Angeles, CAOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Bristol Myers Squibb across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI